ZA201603270B - Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses - Google Patents

Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Info

Publication number
ZA201603270B
ZA201603270B ZA2016/03270A ZA201603270A ZA201603270B ZA 201603270 B ZA201603270 B ZA 201603270B ZA 2016/03270 A ZA2016/03270 A ZA 2016/03270A ZA 201603270 A ZA201603270 A ZA 201603270A ZA 201603270 B ZA201603270 B ZA 201603270B
Authority
ZA
South Africa
Prior art keywords
subpopulations
compositions
human placental
placental perfusate
perfusate cells
Prior art date
Application number
ZA2016/03270A
Other languages
English (en)
Inventor
P Gurney Jodi
Zhang Xiaokui
Herb Stacy
J Hariri Robert
Original Assignee
Anthrogenesis Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anthrogenesis Corp filed Critical Anthrogenesis Corp
Publication of ZA201603270B publication Critical patent/ZA201603270B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/50—Placenta; Placental stem cells; Amniotic fluid; Amnion; Amniotic stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Reproductive Health (AREA)
  • Pregnancy & Childbirth (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
ZA2016/03270A 2013-11-15 2016-05-13 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses ZA201603270B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361905076P 2013-11-15 2013-11-15
US201361905077P 2013-11-15 2013-11-15
PCT/US2014/065665 WO2015073800A2 (en) 2013-11-15 2014-11-14 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Publications (1)

Publication Number Publication Date
ZA201603270B true ZA201603270B (en) 2022-09-28

Family

ID=53058264

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA2016/03270A ZA201603270B (en) 2013-11-15 2016-05-13 Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses

Country Status (11)

Country Link
US (2) US20160279171A1 (enExample)
EP (1) EP3068432A4 (enExample)
JP (4) JP2016537362A (enExample)
KR (3) KR20160098244A (enExample)
CN (2) CN113679740A (enExample)
AU (3) AU2014348454A1 (enExample)
CA (1) CA2930573C (enExample)
MX (2) MX2016006270A (enExample)
RU (1) RU2016123361A (enExample)
WO (1) WO2015073800A2 (enExample)
ZA (1) ZA201603270B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11707491B2 (en) * 2016-11-11 2023-07-25 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Methods of treating neurodegenerative disorders
AU2018234827B2 (en) * 2017-03-15 2024-04-04 Orca Biosystems Inc. Compositions and methods for hematopoietic stem cell transplants
MX2021006402A (es) * 2018-11-30 2021-08-11 Celularity Inc Celulas t-car alogenicas derivadas de placenta y usos de las mismas.

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10001172A1 (de) 2000-01-13 2001-07-26 Max Planck Gesellschaft Templatieren von Feststoffpartikeln mit Polymermultischichten
US20080152629A1 (en) * 2000-12-06 2008-06-26 James Edinger Placental stem cell populations
US7311905B2 (en) * 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR100915483B1 (ko) 2000-12-06 2009-09-03 로버트 제이 하리리 태반 줄기 세포의 회수 방법
JP2004528021A (ja) 2001-02-14 2004-09-16 アンスロジェネシス コーポレーション 分娩後の哺乳動物の胎盤、その使用およびそれに由来する胎盤幹細胞
ES2545899T3 (es) * 2001-02-14 2015-09-16 Anthrogenesis Corporation Placenta post-parto de mamíferos, su uso y células madre placentarias de la misma
US7682803B2 (en) * 2005-10-13 2010-03-23 Anthrogenesis Corporation Immunomodulation using placental stem cells
US7498171B2 (en) * 2002-04-12 2009-03-03 Anthrogenesis Corporation Modulation of stem and progenitor cell differentiation, assays, and uses thereof
AU2005228442A1 (en) * 2004-03-29 2005-10-13 Cytomatrix, Llc Methods for production of regulatory T cells and uses thereof
PT2471905T (pt) * 2005-12-29 2019-01-11 Celularity Inc Populações de células estaminais placentárias
AU2006332679A1 (en) 2005-12-29 2007-07-12 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
PL1981515T3 (pl) * 2006-01-23 2014-02-28 Athersys Inc Leczenie urazów i chorób mózgu za pomocą MAPC
CN105087490A (zh) * 2006-05-11 2015-11-25 脐血科技公司 收集和使用胎盘脐血干细胞的方法
CN101631852A (zh) * 2006-10-23 2010-01-20 人类起源公司 用胎盘细胞群治疗骨缺损的方法和组合物
US10494607B2 (en) * 2007-02-12 2019-12-03 Celularity, Inc. CD34+,CD45−placental stem cell-enriched cell populations
CA2688504A1 (en) * 2007-06-18 2008-12-24 Children's Hospital & Research Center At Oakland Method of isolating stem and progenitor cells from placenta
MX2010003217A (es) * 2007-09-26 2010-07-30 Celgene Cellular Therapeutics Celulas angiogenicas de perfundido de placenta humana.
CA2700617C (en) 2007-09-28 2018-11-06 Celgene Cellular Therapeutics Tumor suppression using human placental perfusate and human placenta-derived intermediate natural killer cells
RU2732240C2 (ru) 2008-11-21 2020-09-14 Антродженезис Корпорейшн Лечение заболеваний, расстройств или патологических состояний легких с использованием плацентарных клеток
EP2405912A2 (en) * 2009-03-12 2012-01-18 University Of South Florida Method of disease-induced and receptor-mediated stem cell neuroprotection
WO2010141654A1 (en) * 2009-06-05 2010-12-09 Anthrogenesis Corporation Improved method of collecting placental cells
US20120177618A1 (en) * 2009-07-14 2012-07-12 Massachusetts Institute Of Technology Hematopoietic stromal progenitor cells and uses thereof
US20110280849A1 (en) 2010-03-26 2011-11-17 Anthrogenesis Corporation Tumor suppression using human placenta-derived intermediate natural killer cells and immunomodulatory compounds
EP2556145B1 (en) * 2010-04-07 2016-07-20 Anthrogenesis Corporation Angiogenesis using placental stem cells
JP5996533B2 (ja) * 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
KR20210144909A (ko) 2010-12-17 2021-11-30 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 면역-관련 질환 및 장애의 치료
KR20140003473A (ko) * 2010-12-17 2014-01-09 안트로제네시스 코포레이션 양막 유래 부착성 세포를 사용한, 척수 손상 및 외상성 뇌 손상의 치료
US20120171180A1 (en) 2010-12-30 2012-07-05 Sascha Abramson Compositions comprising amnion derived adherent cells and platelet-rich plasma
WO2013055476A1 (en) * 2011-09-09 2013-04-18 Anthrogenesis Corporation Treatment of amyotrophic lateral sclerosis using placental stem cells
KR20220166873A (ko) 2012-08-13 2022-12-19 셀룰래리티 인코포레이티드 자연 살해 세포 및 그의 용도
WO2014063035A2 (en) * 2012-10-19 2014-04-24 Anthrogenesis Corporation Treatment of pain using amnion derived adherent cells

Also Published As

Publication number Publication date
JP2016537362A (ja) 2016-12-01
CN105916521A (zh) 2016-08-31
WO2015073800A8 (en) 2015-12-17
WO2015073800A3 (en) 2015-07-02
CA2930573A1 (en) 2015-05-21
MX2016006270A (es) 2016-09-07
JP2022020622A (ja) 2022-02-01
KR20210121277A (ko) 2021-10-07
CA2930573C (en) 2023-12-05
AU2020202182A1 (en) 2020-04-16
MX2021003799A (es) 2021-06-04
US20190117705A1 (en) 2019-04-25
RU2016123361A (ru) 2017-12-20
JP2020019777A (ja) 2020-02-06
KR20160098244A (ko) 2016-08-18
AU2022215291A9 (en) 2022-11-24
EP3068432A4 (en) 2017-04-19
JP2024016037A (ja) 2024-02-06
KR20240023709A (ko) 2024-02-22
AU2022215291A1 (en) 2022-09-01
US20160279171A1 (en) 2016-09-29
WO2015073800A2 (en) 2015-05-21
EP3068432A2 (en) 2016-09-21
CN113679740A (zh) 2021-11-23
AU2014348454A1 (en) 2016-06-02

Similar Documents

Publication Publication Date Title
IL272324B (en) Methods, systems and preparations for cellular conversion using protein-induced in vivo cellular programming
HUE048666T2 (hu) Mezõgazdasági endofita-növény kompozíciók és alkalmazási eljárások
GB2535911B (en) Strigolactone formulations and uses thereof
IL237625A0 (en) Antibodies against m-cam, preparations containing them and their uses
ZA201505004B (en) Solid solution compositions and use in severe pain
IL236348A0 (en) Anti-Jagad antibodies, preparations containing them and their uses
EP2968474A4 (en) SKIN COMPOSITIONS AND USES
IL235004A0 (en) Antibodies against fgfr2, preparations containing them and their uses
IL241355B (en) Pyrazole-amide compounds, preparations containing them and their uses
EP2971030B8 (en) Oligosaccharide compositions, glycoproteins and methods to produce the same in prokaryotes
EP3081348A4 (en) Robot hand, robot, and robot cell
ZA201505814B (en) Stable compositions comprising heparinoid, acute-acting anesthetic, and buffer
GB2519982B (en) Fungicidal composition and the use thereof
SG11201510209SA (en) Cell populations, methods of transdifferention and methods of use thereof
IL276126B (en) Preparations containing l-4-chloroquinonerine and their uses
EP2976091C0 (de) Antioxidativ wirksame zusammensetzung und deren verwendung
GB2516838B (en) Fungicidal compositions and their use
ZA201603270B (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
EP2970883B8 (en) Enhanced placental stem cells and uses thereof
HK1228286A (en) Compositions comprising human placental perfusate cells, subpopulations thereof, and their uses
AU2013903103A0 (en) Acrolein-Polymers, their Compositions and In-vivo Uses
HK1228267A1 (en) Methods, systems and compositions relating to cell conversion via protein induced in-vivo cell reprogramming
GB201320632D0 (en) Electrochemical cells and components thereof
GB201308242D0 (en) Compositions and uses thereof
GB201306047D0 (en) Cell preservation